Perioperative management of hyperglycemic patients undergoing surgery: an observational cross sectional study in a tertiary care hospital
Abstract
Background: Diabetes poses an additional risk during anesthesia, yet there is a lack of sufficient Indian data on perioperative antidiabetic drug use and its implications. This droves us to conduct the study.
Methods: Cross-sectional, observational study, conducted in a tertiary care hospital's general surgery and orthopaedics wards. Data collected from the first anaesthetist visit to 24 hours postoperative period included antidiabetic medications, anesthesia drugs, blood sugar levels, co-morbidities, concomitant medications, and intravenous (IV) fluids. Descriptive statistics and parametric tests were used for analysis.
Results: The study comprised 180 patients (62.8% males, median age 56 years), with diabetes duration predominantly between 1-5 years (28.3%). Preoperatively, metformin was the most prescribed oral hypoglycemic agent (72.2%), decreasing to 56.67% postoperatively. Intraoperatively, only 1.6% received insulin, while 98.4% received no drugs. Common postoperative antidiabetic agents included insulin BD (n=48). General surgery (73.3%) and orthopedics (26.7%) contributed 132 and 48 patients, respectively, with spinal anesthesia (68.3%) and bupivacaine (75.4%) being most prevalent. Blood glucose during surgery was effectively monitored. Hypertension (52.8%) was the most common co-morbidity, and Ringer lactate (60.8%) was the predominant IV fluid.
Conclusions: Adequate perioperative antidiabetic management was observed in hyperglycemic patients.
How strong is the evidence?
Evidence Hub reads this as a cross-sectional, done in people. Its evidence level is 4 of 5 (Low · observational). Observational designs can show an association but not prove cause. Reported size: 180 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.